Genome-editing with CRISPR has emerged as a technology with broad therapeutic potential. 2 However, it is unclear whether CRISPR will elicit innate immune responses, which could impact both 3 positively and negatively on the desired therapeutic effects. Here, we have examined the immune-4 stimulatory properties of different variants of guide RNAs (gRNAs) -in vitro transcribed gRNA 5 (IVT-gRNA) and synthetic gRNAs with or without chemical modifications, full-length or duplexed. 6
Introduction 1
CRISPR is now broadly used in basic and translational research. The technology was originally 2 invented for its site-specific nuclease activity (Jinek et CRISPR is crucial as the potential immune reaction could conceivably lead to compromised gene 7 editing efficiency and clearance of modified cells. It has been noted that long-term Cas9 exposure 8 elicits Cas9 specific T-cell expansion and antibody production in mice (Chew et al. 2016 ). Prior to 9 adaptive immune responses to Cas9 protein, the CRISPR can be sensed by the innate immune system 10 which can detect foreign nucleic acids and is normally involved in recognition of invading viruses 11 and bacteria. So far, it is unclear if gRNA -another component of CRISPR -will be recognized by 12 the targeted cells. The gRNA which guides Cas9/gRNA complex to an intended genomic locus is a 13 ~100-nucleotides sequence consisting of both single-and double-stranded structures. It can be 14 transcribed intracellularly driven by U6 promoter or can be delivered directly in the RNA format 15 from in vitro transcription or synthesis. The in vitro transcribed gRNA (IVT-gRNA) together with 16
Cas9 mRNA have been commonly used for microinjection into one-cell-stage embryos to quickly 17 generate gene-modified animals (Niu et al. 2014 ). The synthetic gRNA with chemical modifications 18 has shown superior efficiency and demonstrates potential in gene therapy research (Hendel et al. 2015 ; 19
Dever et al. 2016). Compared to the well characterized nuclease activity, it is unclear if administration 20
of gRNAs causes additional effects in the intracellular environment such as innate immune response. 21
In this study, we investigated the innate immune stimulatory properties of gRNAs from different 22 sources -in vitro transcribed gRNA and a variety of synthetic gRNAs. In several cell types, we found 23 that IVT-gRNA, but none of the synthetic gRNAs, elicits strong expression of a panel of cytokines 24
including IFNB1, TNFA, IL6 and CXCL10 while maintaining nuclease activity. Taking advantage of 25 this dual function of IVT-gRNAs, we demonstrated that they induced highly efficient antiviral 26 response and provided bystander protection to the neighbouring non-transfected cells. By using a 27 HSV-1 infection mouse model, we further extend the robust antiviral effects of IVT-gRNA in vivo. THP1   THP1  THP1  THP1   THP1  THP1 THP1
The sequence and secondary structure of a CCR5 locus targeting IVT-gRNA with a 5' triphosphate 1 (ppp) moiety is illustrated in Fig. 2A . We first investigated the mechanism of IVT-gRNA induced 2 innate immune sensing using 293T cell lines knockout of three cytoplasmic RNA sensors -retinoic 3 acid-inducible gene-I (RIG-I), melanoma differentiation-associated gene 5 (MDA5) and protein 4 kinase R (PKR). While knockout of MDA5 and PKR preserved IFNB1 induction, knockout of RIG-I 5 completely abolished IVT-gRNA-induced IFNB1 expression indicating RIG-I to be the primary 6 sensor of IVT-gRNA (Fig. 2B) . Using the same setting, we investigated mechanism to sense the 7 unmodified Cas9 mRNA and found reduced IFNB1 induction only when RIG-I was knockout 8 (Supplemental_Fig_S3A). Next, we investigated which adaptor molecule for nucleic acids sensors 9 was involved in the IVT-gRNA sensing pathway. We found that cells lacking mitochondrial antiviral-10 signaling protein (MAVS), but not cells lacking stimulator of IFN genes (STING) exhibited reduced 11 capacity to evoke IFNB1 expression following IVT-gRNA transfection ( promote IFNB1 production but significantly lower than the wild-type counterpart ( Fig. 2D and  17 Supplemental_Fig_S3B). To investigate the mechanism in IVT-gRNA sensing, we pre-treated the 18 IVT-gRNA with Alkaline Phosphatase (CIP) to remove the 5' triphosphate group before transfection. 19
This treatment reduced the induction of IFNB1 in THP1-derived macrophages (Fig. 2E) . Furthermore, 20 the reduced induction of IFNB1 was recapitulated when capped IVT-gRNA was used for transfection 21 (Fig. 2E) . As the IVT-gRNA can be assembled into ribonucleoprotein (RNP) with Cas9 protein in 22 vitro, we therefore ask whether preassembly can minimize IVT-gRNA sensing. Indeed, we found 23 significantly lower of IFNB1 production likely due to preassembly excluded the binding of RIG-I to 24 gRNA (Fig. 2F) . Together, these data suggest RIG-I recognition to the 5' triphosphate group but not 25 the secondary RNA structure is the main contributor to IVT-gRNA induced immune sensing. 
Gene disruption efficiency of gRNA variants 14
To compare the genome-editing efficiency of different in vitro transcribed and synthetic gRNAs, we 15 generated a 293T cell line constitutively expressing Cas9, and performed T7 endonuclease I (T7EI) 16 assay following gRNA transfection. All the synthetic gRNAs showed higher efficiency than IVT-1 gRNA, in particular, the chemically modified gRNAs (Fig. 3A) . Although addition of a cap to 5'-end 2 of IVT-gRNA was detrimental for obtaining efficient genome-editing, uncapped IVT-gRNA 3 maintained 10% efficiency (Fig. 3A) . When the Cas9 was expressed following transfection of 4 chemically modified Cas9 mRNA which is immune silent, IVT-gRNA, full-length unmodified and 5 full-length modified gRNAs showed efficiency of 10%, 14% and 22%, respectively, similar pattern 6 as in 293T-Cas9 cells (Fig. 3B) . However, when we preassembled the gRNAs with Cas9 protein to 7 RNP, IVT-gRNA and full-length unmodified gRNA presented same efficiency (Fig. 3C) . Notably, 8 preassembly did not remove the gap of efficiency between full-length unmodified and modified 9 gRNA (Fig. 3C ) -a phenomenon that has been noticed previously (Hendel et al. 2015) . To investigate 10 influences of RNA sensors on the efficiency of genome editing, we generated RIG-I, PKR and MDA5 11 knockout cell lines derived from the HEK293T-Cas9 cells. In all tested knockout and wild-type 293T 12 cells, chemically modified full-length gRNA consistently had higher gene disruption efficiency than 13 its unmodified counterpart indicating factors other than the innate RNA-sensing proteins being 14 responsible for lower gene editing by unmodified full-length gRNA ( Interestingly, however, HSV-1 infection in HaCaT did not induce detectable IFNB1 and MX1 mRNA 28 nor type I IFN bioactivity (Supplemental_Fig_S4A-C). As unmodified Cas9 mRNA also induces 29 cytokines (Supplemental_Fig_S2), we examined whether we could maximize immune responses by 30 combining IVT-gRNA and unmodified Cas9 mRNA instead of its modified counterpart. Indeed, IVT-31 gRNA has a tendency to induce more IFNB1 production when combined with unmodified Cas9 1 mRNA instead of modified one (Fig. 4B) . Notably, the immune maximized combination did not 2 affect the efficiency of gene disruption when testing on endogenous CCR5 locus (Fig. 4C) . Next, we 3 compared the antiviral activity of different CRIPSR combination against HSV1-GFP by measuring 4 the percentage of GFP positive cells. We found the immune silent combination -full-length 5 unmodified gRNAs and modified Cas9 mRNA only reduced GFP modestly but significantly 6 compared to mock-treated control cells (Fig. 4D) . In contrast, in the immune maximized group, IVT-7 gRNA and unmodified Cas9 mRNA strongly suppressed viral gene expression (Fig. 4D) . Therefore, 8
we chose the immune maximized combination for further investigation. We evaluated the antiviral 9 activity of two gRNAs targeting to HSV-1 UL8 and UL29 gene, respectively. On day 1, both IVT-10 gRNAs suppressed HSV1-GFP infection significantly ( Fig. 4E and Fig. 4F , and 11
Supplemental_Fig_S4D and 4E, left column). On day 2, the virus infection did progress even in the 12 presence of IVT-gRNA ( Fig. 4G and Fig. 4H , and Supplemental_Fig_S4E, right column and 4F). 13
However, the IVT gRNA-treated cells preserved intact colony structure in sharp contrast to the mock 14 which failed to form large colonies highlighted by dash lines (Fig. 4H and Supplemental_Fig_S4E, 15 right column) indicating the IVT-gRNAs provide bystander protection to the neighbouring non-16 transfected cells. In addition, the robust antiviral effects from IVT-gRNA was replicated by the plaque 17 assay using the supernatants from IVT-gRNA treated cells from day 1 (Fig. 4I and  18 Supplemental_Fig_S4G). The bystander versus genome-editing-mediated protection from IVT-19 gRNA can be distinguished by microscopy, since not all cells are transfected with the delivered RNAs. 20
We compared the antiviral activity of immunostimulatory and immune silent RNAs. Interestingly, 21 only the immunostimulatory RNA, but not the immune silent RNAs led to protection of large areas 22 of the infected cell culture (Supplemental_Fig_S4H). To examine whether type I IFNs participated 23 in IVT-gRNA-mediated antiviral responses, we generated a IFNAR2 knockout HaCaT line which 24 does not respond to type I IFNs (Supplemental_Fig_S5A, B). In this setting, the immunostimulatory 25 RNAs, i.e. IVT-gRNA and unmodified Cas9 mRNA induced relatively strong antiviral activity but 26 to a much less extent than in wild-type cells (Fig. 4J) . Importantly, IFNAR2 KO cells, failed to provide 27 bystander protection to non-transfected cells as no large intact colony was found (Fig. 4K) . 28
Collectively, these data demonstrate that the type I IFN system provides potent adding benefits to the 29 CRISPR-mediated antiviral activity. 
The antiviral effects of dual functioning gRNA in vivo 14
To strengthen the concept of using dual functioning IVT-gRNA for antiviral purpose, we adopted a 15 HSV-1 intraperitoneal infection model. As shown Fig. 5A , we added IVT-gRNA 24 h after infection, 16 to mimic a clinically relevant situation with initiation of treatment after infection. Interestingly, 17 intravenous injection of IVT-gRNA encapsulated in nanoparticles, reduced viral load to below 18 detection limit in the spleen in contrast to what was observed in the vehicle treated group (Fig. 5B) . 19
In agreement with this, we observed fewer virus-positive cells in the liver of mice receiving IVT-20 gRNA, which also generally stained less intensely for virus antigen (Fig. 5C) . These results suggest 21 that IVT-gRNA possess potent antiviral activity in vivo. This urges further exploration.
Methods 1

Mice 2
The CRISPR/Cas9 knock-in mice constitutively express Cas9 endonuclease (B6J.129(Cg)-3
Igs2
tm1.1(CAG-cas9*)Mmw /J) were obtained from The Jackson Laboratory. All experiments were carried 4 out at the University of Aarhus and approved by Danish government authorities. In the infected 5 groups, mice were infected with HSV1-GFP (10 6 PFU/mouse) at 1-month age by IP injection. The 6 infected mice were either tail vein injected with vehicle (phosphate buffered saline) or IVT-gRNA 7 (40 µg/mouse) complexed with in vivo-jetPEI®-Gal (Polyplus). 8
Cells lines 9
To generate 293T cell line knockout of PKR, a gRNA sequence (5'-ttatccatggggaattacat-3') targeting 10 to PKR was cloned into lentiCRISPRv2 puro plasmid (Addgene plasmid # 98290). The acquired 11 gRNA plasmid was then used to produce lentiviral vector for infection of wild-type 293T cells. The ISG54. Thus, upon type I IFN stimulation, the HEK-Blue cells secreted SEAP which is detected using 28 its detection reagent QUANTI-Blue TM by an absorbance shift measured at 620 nm using ELx808 29 absorbance microplate readers (BioTek). 30
T7 endonuclease I assay 31
293T-Cas9 were transfected with gRNAs alone and 293T cells were co-transfected with gRNAs and 1 Cas9 mRNA or recombinant protein using Lipofectamine 2000 (ThermoFisher Scientific). 48 h after 2 transfection, the cells were harvested and incubated with QuickExtract (Epicentre). The yields were 3 used as templates for PCR amplification using Phusion Master Mix (ThermoFisher Scientific). The 4 PCR products were incubated with 1 µl T7EI nuclease (NEB) in the presence of NEB buffer 2 at 5 42°C for 30 min after denaturation and re-annealing. The cleavage products were separated on a 1.5% 6 agarose gel and stained with ethidium bromide. The percentage of indels was determined as previous 
Immunohistochemistry 4
Liver tissues were fixated in 10% formalin, embedded in paraffin, and cut at 4 µm. The tissues 5 sections submitted to antigen retrieval in a citrate buffer and blocked in 5% BSA. The sections were 6 incubated overnight with primary antibody for HSV2 (1/500 dilution, B0116; Dako) and the stain 7 was visualized with appropriate secondary antibody and HRP. Hematoxylin was used to stain cell 8 nuclei. 9
Statistical analysis 10
Data are presented as mean ± SD in all experiments (n≥3). Student's t-tests were performed as 11 indicated (* indicates statistical significance, P<0.05). 12
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